Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Bergmann-Leitner ES, Duncan EH, Mease RM, Angov E.

Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.

2.

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD.

Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.

3.

Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.

Burns JM Jr, Miura K, Sullivan J, Long CA, Barnwell JW.

Malar J. 2016 Mar 15;15:159. doi: 10.1186/s12936-016-1226-5.

4.
5.
6.

Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ.

J Immunol. 2013 Feb 1;190(3):1135-47. doi: 10.4049/jimmunol.1201455. Epub 2013 Jan 4.

7.

Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.

Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.

Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004. Epub 2010 Feb 17.

PMID:
20170765
8.
10.

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.

Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA.

Infect Immun. 2005 Jan;73(1):287-97.

11.

Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.

Spring MD, Chelimo K, Tisch DJ, Sumba PO, Rochford R, Long CA, Kazura JW, Moormann AM.

Infect Immun. 2010 Oct;78(10):4431-41. doi: 10.1128/IAI.00415-10. Epub 2010 Aug 9.

12.

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ.

PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.

13.

Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.

Reed ZH, Kieny MP, Engers H, Friede M, Chang S, Longacre S, Malhotra P, Pan W, Long C.

Vaccine. 2009 Mar 4;27(10):1651-60. doi: 10.1016/j.vaccine.2008.10.093. Epub 2008 Nov 25.

PMID:
19038302
14.

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG; MSP-1 Working Group.

Vaccine. 2006 Apr 5;24(15):3009-17. Epub 2005 Nov 28.

PMID:
16356603
15.

Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Singh B, Cabrera-Mora M, Jiang J, Galinski M, Moreno A.

Vaccine. 2010 Mar 19;28(14):2580-92. doi: 10.1016/j.vaccine.2010.01.019. Epub 2010 Jan 22.

17.

A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge.

Obaldia N 3rd, Stockelman MG, Otero W, Cockrill JA, Ganeshan H, Abot EN, Zhang J, Limbach K, Charoenvit Y, Doolan DL, Tang DC, Richie TL.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00539-16. doi: 10.1128/CVI.00539-16. Print 2017 Apr.

18.

Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.

Lynch MM, Cernetich-Ott A, Weidanz WP, Burns JM Jr.

Clin Vaccine Immunol. 2009 Mar;16(3):293-302. doi: 10.1128/CVI.00230-08. Epub 2008 Dec 30.

19.

A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Alaro JR, Partridge A, Miura K, Diouf A, Lopez AM, Angov E, Long CA, Burns JM Jr.

Infect Immun. 2013 Oct;81(10):3843-54. doi: 10.1128/IAI.00522-13. Epub 2013 Jul 29.

20.

Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Yoshida S, Nagumo H, Yokomine T, Araki H, Suzuki A, Matsuoka H.

PLoS One. 2010 Oct 28;5(10):e13727. doi: 10.1371/journal.pone.0013727.

Supplemental Content

Support Center